Myriad Genetics, Inc. (MYGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Myriad Genetics, Inc. (MYGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 15, 2026

Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance

Myriad announced select unaudited preliminary results for the 4th quarter and full year ended Dec. 31, 2025, provided full year 2026 financial guidance.

GlobeNewsWire • Jan 12, 2026

Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference

SALT LAKE CITY, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Sam Raha, president and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 14, at 5:15 pm PT (8:15 pm ET).

GlobeNewsWire • Jan 5, 2026

Should Myriad Genetics Stock Stay in Your Portfolio Right Now?

MYGN shows growth potential from new genetic test launches and a refreshed CCC strategy, but revenue pressure from GeneSight coverage loss remains a drag.

Zacks Investment Research • Dec 30, 2025

Why Is Myriad (MYGN) Up 8.7% Since Last Earnings Report?

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Dec 3, 2025

Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health

BOSTON and SALT LAKE CITY and FULTON, Md., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Clairity, Myriad Genetics, Inc. (NASDAQ: MYGN), and MagView, today announced a joint collaboration in an effort to identify more women at high risk for breast cancer, with the goal of addressing a critical gap in breast cancer risk assessment without creating additional administrative burdens.

GlobeNewsWire • Nov 25, 2025

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

SALT LAKE CITY, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will participate in two upcoming healthcare conferences. The 7th Annual Wolfe Research Healthcare Conference with a fireside chat on Tuesday, Nov. 18, 2025, at 1:20 pm ET.

GlobeNewsWire • Nov 11, 2025

Myriad Genetics: Downgrading To "Hold" Rating On Break-Even Q3 Earnings

Myriad Genetics (MYGN) is downgraded from a "Buy" to "Hold" due to flat Q3 2025 earnings and limited near-term revenue growth. MYGN's Hereditary Cancer Test and Prolaris segments show volume growth, but revenue gains remain modest and expansion impacts are delayed. Upcoming addition launches, including expanded MyRisk HCT and AI-powered Prolaris, offer potential but won't affect results until mid-to-late 2026.

Seeking Alpha • Nov 5, 2025

Myriad Genetics, Inc. (MYGN) Q3 2025 Earnings Call Transcript

Myriad Genetics, Inc. ( MYGN ) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST Company Participants Matthew Scalo - Senior Vice President of Investor Relations Samraat Raha - President, CEO & Director Mark Verratti - Chief Operating Officer Ben Wheeler - CFO & Principal Accounting Officer Conference Call Participants Puneet Souda - Leerink Partners LLC, Research Division David Westenberg - Piper Sandler & Co., Research Division Kyle Boucher - TD Cowen, Research Division Lauren Timmins - Jefferies LLC, Research Division Ricki Levitus - Guggenheim Securities, LLC, Research Division Lu Li - UBS Investment Bank, Research Division Benjamin Mee - Stephens Inc., Research Division John Wilkin - Craig-Hallum Capital Group LLC, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the Myriad Genetics' Third Quarter 2025 Earnings Conference Call.

Seeking Alpha • Nov 4, 2025

Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution

Highl ights Third quarter 2025 revenue of $205.7 million decreased by 4% year-over-year but was flat when excluding previously discussed headwinds 1 of $8.1 million , consistent with management expectations . Third quarter 2025 hereditary cancer testing revenue and volume grew 3% and 11% year-over-year, respectively.

GlobeNewsWire • Nov 3, 2025